Sirus Pharma Marketing Pvt Ltd
Manufactures and markets medicines, medical preparations, chemicals, surgical goods, and equipment.
1996 | Khasi Hills, Meghalaya (India) | Active
Sirus Pharma Marketing Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 28 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -13.59%
- Profit Growth -50.06%
- Ebitda -240.43%
- Net Worth 38.56%
- Total Assets 19.74%
About Sirus Pharma Marketing
Sirus Pharma Marketing Pvt Ltd (SPMPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 May 1996 and has a history of 28 years and nine months. Its registered office is in Khasi Hills, Meghalaya, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Arup Das and Nirmal Das serve as directors at the Company.
Company Details
- Location
Khasi Hills, Meghalaya, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24236ML1996PTC004744
- Company No.
004744
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 1996
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Pharma
Healthcare
Who are the key members and board of directors at Sirus Pharma Marketing?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Das  | Managing Director | 07-May-1996 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arup Das | Director | 07-May-1996 | Current |
Financial Performance of Sirus Pharma Marketing.
Sirus Pharma Marketing Pvt Ltd, for the financial year ended 2018, experienced significant reduction in revenue, with a 13.59% decrease. The company also saw a substantial fall in profitability, with a 50.06% decrease in profit. The company's net worth Soared by an impressive increase of 38.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sirus Pharma Marketing?
In 2019, Sirus Pharma Marketing had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sirus Pharma Marketing?
Unlock and access historical data on people associated with Sirus Pharma Marketing, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sirus Pharma Marketing, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sirus Pharma Marketing's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
